SoftBank and Heritage Provider Network were among the investors who co-led a series C round for Intervenn Biosciences, which is developing precision medicine.

US-based precision medicine technology developer Intervenn Biosciences has closed a $201m series C round co-led by telecoms firm SoftBank and health system Heritage Provider Network.

Irving Investors and Highside Capital Management also co-led the round, which was filled out by Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.

Intervenn Biosciences has developed an artificial intelligence-equipped glycoproteomics platform and a liquid biopsy assay for immune checkpoint inhibitor response prediction. It will use the series C funding to accelerate technology development…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn